ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shares saw unusually-high trading volume on Wednesday . Approximately 22,504 shares were traded during mid-day trading, a decline of 87% from the previous session’s volume of 179,017 shares.The stock last traded at $7.80 and had previously closed at $9.50.

CTRV has been the subject of several recent research reports. ValuEngine raised shares of ContraVir Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Maxim Group downgraded shares of ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Barclays PLC raised its stake in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 229.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,480 shares of the biopharmaceutical company’s stock after purchasing an additional 124,958 shares during the quarter. Barclays PLC owned 1.08% of ContraVir Pharmaceuticals worth $50,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.07% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

Read More: Resistance Level

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.